Caring Ambassadors Program

Hepatitis C Newsletter

June 2012

Clinical Trials, Cohort Studies, Pilot Studies

Proton Pump Inhibitors Increase the Incidence of Bone Fractures in Hepatitis C Patients. Mello M, Weideman RA, Little BB, et al. Dig Dis Sci. 2012 May 22. [Epub ahead of print]

A sustained virological response prevents development of insulin resistance in chronic hepatitis C patients. Aghemo A, Prati GM, Rumi MG, et al. Hepatology. 2012 May 22. doi: 10.1002/hep.25867. [Epub ahead of print]

Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV Coinfection. Lo Re V 3rd, Volk J, Newcomb CW, et al. Hepatology. 2012 May 22. doi: 10.1002/hep.25866. [Epub ahead of print]

Refinement of stopping rules during treatment of hepatitis c-genotype 1 infection with boceprevir combined with peginterferon/ribavirin. Jacobson IM, Marcellin P, Zeuzem S, et al. Hepatology. 2012 May 22. doi: 10.1002/hep.25865. [Epub ahead of print]

Factors that Predict Response of Patients with HCV Infection to Boceprevir. Poordad F, Bronowicki JP, Gordon SC, et al. Gastroenterology. 2012 May 21. [Epub ahead of print]

strongest predictor of a SVR, regardless of polymorphisms in IL-28B. © 2012 AGA Institute.

Difference in serum complement component C4a levels between hepatitis C virus carriers with persistently normal alanine aminotransferase levels or chronic hepatitis C.

Imakiire K, Uto H, Sato Y, et al. Mol Med Report. 2012 May 21. doi: 10.3892/mmr.2012.924. [Epub ahead of print]

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of

chronic hepatitis C patients. Lee SS, Roberts SK, Berak H, et al. Liver Int. 2012 May 24. doi: 10.1111/j.1478-3231.2012.02819.x. [Epub ahead of print]

Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. Stättermayer AF, Rutter K, Beinhardt S, et al. J Hepatol. 2012 May 24. [Epub ahead of print]

Impact of sirolimus and tacrolimus on mortality & graft loss in liver transplant recipients with and without HCV - an analysis of the SRTR database. Watt K, Dierkhising R, Heimbach J, Charlton M. Liver Transpl. 2012 May 29. doi: 10.1002/lt.23479. [Epub ahead of print]

Association of chronic hepatitis C with recurrent brief depression. Carta MG, Angst J, Moro MF, et al. J Affect Disord. 2012 May 18. [Epub ahead of print]

Treatment of Recurrent HCV Infection Following Liver Transplantation: Results of  a Multicenter, Randomized, versus placebo, Trial of ribavirin alone as maintenance therapy after one year of Peginterferon Alfa-2A plus Ribavirin. Calmus Y, Duvoux C, Pageaux G, et al. J Hepatol. 2012 May 18. [Epub ahead of print]

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. Ogawa E, Furusyo N, Murata M, et al. J Hepatol. 2012 May 18. [Epub ahead of print]

Histological evolution of hepatitis C virus infection after renal transplantation.

de Oliveira Uehara SN, Emori CT, Pereira PD, et al. Clin Transplant. 2012 May 17. doi: 10.1111/j.1399-0012.2012.01635.x. [Epub ahead of print]

Correlation of viral load with bone marrow and hematological changes in pale patients with chronic hepatitis C virus. Abou El Azm AR, El-Bate H, et al. Arch Virol. 2012 May 9. [Epub ahead of print]

Prevalence of fibromyalgia among patients with chronic hepatitis C infection: relationship to viral characteristics and quality of life. Mohammad A, Carey JJ, Storan E, et al. J Clin Gastroenterol. 2012 May-Jun;46(5):407-12.

Treatment Results of Chronic Hepatitis C Genotype 5 and 6 Infections in Germany.

Mauss S, Berger F, Vogel M, Pfeiffer-Vornkahl H, Z et al. Gastroenterol. 2012 May;50(5):441-444. Epub 2012 May 11.

Basic and Applied Science, Pre-Clinical Studies

Sequential immunological analysis of HBV/HCV co-infected patients during

Peg-IFN/RBV therapy. Kondo Y, Ueno Y, Ninomiya M, et al. J Gastroenterol. 2012 May 16. [Epub ahead of print]

Preclinical Characterization of JTK-853, a Novel Non-nucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase. Ando I, Adachi T, Ogura N, et al. Antimicrob Agents Chemother. 2012 May 21. [Epub ahead of print]

MK-5172, a selective inhibitor of Hepatitis C Virus NS3/4a protease with broad activity across genotypes and resistant variants. Summa V, Ludmerer SW, McCauley JA, et al. Antimicrob Agents Chemother. 2012 May 21. [Epub ahead of print]

SKI-1/S1P inhibition: A promising surrogate to statins to block Hepatitis C virus  replication. Blanchet M, Seidah NG, Labonté P. Antiviral Res. 2012 May 22. [Epub ahead of print]

Chronic Hepatitis C Virus infection breaks tolerance and drives polyclonal expansion of autoreactive B cells. Roughan JE, Reardon KM, Cogburn KE, et al. Clin Vaccine Immunol. 2012 May 23. [Epub ahead of print]

Impact of Low-Dose Ritonavir on Danoprevir Pharmacokinetics: Results of Computer-Based Simulations and a Clinical Drug-Drug Interaction Study. Reddy MB, Chen Y, Haznedar JO, et al. Clin Pharmacokinet. 2012 May 24. doi: 10.2165/11599700-000000000-00000. [Epub ahead of print]

Modeling Quasispecies and Drug Resistance in Hepatitis C Patients Treated with a

Protease Inhibitor. Rong L, Ribeiro RM, Perelson AS. Bull Math Biol. 2012 May 26. [Epub ahead of print]

Population Pharmacokinetics and Pharmacodynamics of Ribavirin in Patients with

Chronic Hepatitis C Genotype 1 Infection. Jin R, Fossler MJ, McHutchison JG, Howell CD, Dowling TC. AAPS J. 2012 May 26. [Epub ahead of print]

The variable N terminal region of DDX5 contains structural elements and auto-inhibits its interaction with NS5B of hepatitis C virus. Dutta S, Gupta G, Choi YW, et al. Biochem J. 2012 May 28. [Epub ahead of print]

Liver X receptor α-mediated regulation of lipogenesis by core and NS5A proteins

contributes to HCV-induced liver steatosis and HCV replication. García-Mediavilla MV, Pisonero-Vaquero S, Lima-Cabello E, et al. Lab Invest. 2012 May 28. doi: 10.1038/labinvest.2012.88. [Epub ahead of print]

Hepatocytes that Express Variants of Cyclophilin A are Resistant to HCV Infection and Replication. von Hahn T, Schiene-Fischer C, Van ND, et al. Gastroenterology. 2012 May 8. [Epub ahead of print]

HIV/HCV Coinfection

Buprenorphine for Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Patients: Does It Serve as a Bridge to Hepatitis C Virus Therapy? Taylor LE, Maynard MA, Friedmann PD, et al. J Addict Med. 2012 May 18. [Epub ahead of print]

Sustained Virological Response to Interferon Plus Ribavirin Reduces Non-Liver-Related Mortality in Patients Coinfected With Human Immunodeficiency Virus and Hepatitis C Virus. Berenguer J, Rodríguez E, Miralles P, et al. Clin Infect Dis. 2012 May 18. [Epub ahead of print]

Virological responses during treatment for recent hepatitis C virus: Potential benefit for ribavirin use in HCV/HIV co-infection. Grebely J, Hellard M, Applegate T, et al. AIDS. 2012 May 19. [Epub ahead of print]

Hepatitis C viral load, genotype 3 and IL28B CC genotype predict mortality in HIV and hepatitis C coinfected individuals. Clausen LN, Astvad K, Ladelund S, et al. AIDS. 2012 May 19. [Epub ahead of print]

Understanding the Behavioral Determinants of Retention in HIV Care: A Qualitative Evaluation of a Situated Information, Motivation, Behavioral Skills Model of Care Initiation and Maintenance. Smith LR, Fisher JD, Cunningham CO, Amico KR. AIDS Patient Care STDS. 2012 May 21. [Epub ahead of print]

Lower liver-related death in African American Women with HIV/HCV co-infection compared to caucasian and hispanic women. Sarkar M, Bacchetti P, French AL, et al. Hepatology. 2012 May 22. doi: 10.1002/hep.25859. [Epub ahead of print]

HIV and hepatitis C virus coinfection in Canada: challenges and opportunities for reducing preventable morbidity and mortality. Klein M, Rollet K, Saeed S, et al. HIV Med. 2012 May 28. doi: 10.1111/j.1468-1293.2012.01028.x. [Epub ahead of print]

Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study.  Nouraie M, Nekhai S, Gordeuk VR. Sex Transm Infect. 2012 May 24. [Epub ahead of print]

Cost-effective Screening for Acute Hepatitis C Virus Infection in HIV-Infected Men Who Have Sex With Men. Linas BP, Wong AY, Schackman BR, Kim AY, Freedberg KA. Clin Infect Dis. 2012 May 21. [Epub ahead of print]

Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis.

Rasmussen AL, Wang IM, Shuhart MC, et al. Virology. 2012 May 16. [Epub ahead of print]

Hepatic Safety Profile of Fosamprenavir-Containing Regimens in HIV-1-Infected Patients With or Without Hepatitis B or C Coinfection. Ha B, Wine B, Rodriguez-Alcantra F, Shaefer M. HIV Clin Trials. 2012 May-Jun;13(3):171-7.

Complementary and Alternative Medicine

Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Farias MS, Budni P, Ribeiro CM, et al. Gastroenterol Hepatol. 2012 May 17. [Epub ahead of print]

Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as

predictors of antiviral response in chronic hepatitis C. Falleti E, Bitetto D, Fabris C, et al.

Hepatology. 2012 May 18. doi: 10.1002/hep.25848. [Epub ahead of print]

D-Livering The Message: The Importance of Vitamin D Status in Chronic Liver Disease. Kitson MT, Roberts SK. J Hepatol. 2012 May 22. [Epub ahead of print]

Recent Progress on Anti-Liver Fibrosis Candidates in Patents of Herbal Medicinal Products. Wang XB, Feng Y, Wang N, et al.  Recent Pat Food Nutr Agric. 2012 May 15. [Epub ahead of print]

Effect of soy protein supplementation in patients with chronic hepatitis C: A randomized clinical trial.

Oliveira LP, de Jesus RP, Boulhosa RS, et al. World J Gastroenterol. 2012 May 14;18(18):2203-11.


Epidemiology, Diagnostics, and Miscellaneous Works

Notes from the field : hepatitis C virus infections among young adults – rural Wisconsin, 2010. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 May 18;61:358.

Investigation of viral hepatitis infections possibly associated with health-care delivery - New York City, 2008-2011. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2012 May 18;61:333-8.

Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings. Vickerman P, Martin N, Turner K, Hickman M. Addiction. 2012 May 7. doi: 10.1111/j.1360-0443.2012.03932.x. [Epub ahead of print]

The burden of viral hepatitis C in Europe: a propensity analysis of patient outcomes. Dacosta Dibonaventura M, Yuan Y, Wagner JS, et al. Eur J Gastroenterol Hepatol. 2012 May 18. [Epub ahead of print]

Colonial history and contemporary transmission shape the genetic diversity of hepatitis C virus genotype 2 in Amsterdam. Markov PV, van de Laar TJ, Thomas XV, et al. J Virol. 2012 May 9. [Epub ahead of print]

Hepatitis C prevalence in injecting drug users in Europe, 1990-2007: Impact of study recruitment setting. Rondy M, Wiessing L, Hutchinson SJ, et al. Epidemiol Infect. 2012 May 17:1-10. [Epub ahead of print]

Hepatitis C Virus in Arab World: A State of Concern.

Daw MA, Dau AA. ScientificWorldJournal. 2012;2012:719494. Epub 2012 May 2.

Blood transfusion practice in a rural hospital in Northern Ghana, Damongo, West Gonja District. Kubio C, Tierney G, Quaye T, et al. Transfusion. 2012 May 21. doi: 10.1111/j.1537-2995.2012.03709.x. [Epub ahead of print]

Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs. Treloar C, Hull P, Dore GJ, Grebely J. Drug Alcohol Rev. 2012 May 21. doi: 10.1111/j.1465-3362.2012.00468.x. [Epub ahead of print]

Provider and Patient Correlates of Provider Decisions to Recommend HCV Treatment

to HIV Co-Infected Patients. Wagner G, Osilla KC, Garnett J, et al. J Int Assoc Physicians AIDS Care (Chic). 2012 May 7. [Epub ahead of print]

Male IDUs who have sex with men in England, Wales and Northern Ireland: are they at greater risk of bloodborne virus infection and harm than those who only have sex with women? Marongiu A, Hope VD, Parry JV, Ncube F. Sex Transm Infect. 2012 May 23. [Epub ahead of print]

New antiviral therapies in the management of HCV infection. Farnik H, Zeuzem S.

Antivir Ther. 2012 May 25. doi: 10.3851/IMP2127. [Epub ahead of print]

The National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor Studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): Twenty Years of Research to Advance Blood Product Safety and Availability. Kleinman S, King MR, Busch MP, et al. Transfus Med Rev. 2012 May 24. [Epub ahead of print]

Evaluation of MR imaging with T1 and T2* mapping for the determination of hepatic

iron overload. Henninger B, Kremser C, Rauch S, et al. Eur Radiol. 2012 May 30. [Epub ahead of print]

Utilization of hepatitis C antibody-positive livers: genotype dominance is virally  determined. O'Leary JG, Neri MA, Trotter JF, et al. Transpl Int. 2012 May 30. doi: 10.1111/j.1432-2277.2012.01498.x. [Epub ahead of print]

Hepatitis C transmission due to contamination of multidose medication vials: Summary of an outbreak and a call to action. Branch-Elliman W, Weiss D, Balter S, Bornschlegel K, Phillips M. Am J Infect Control. 2012 May 25. [Epub ahead of print]

Impact of disease severity on health care costs in patients with chronic hepatitis C (CHC) virus infection.Gordon S, Pockros P, Terrault N, et al.  Hepatology. 2012 May 18. doi: 10.1002/hep.25842. [Epub ahead of print]

Evolution of hepatitis C virus hypervariable region 1 in chronically infected children.

Jackowiak P, Kowala-Piaskowska A, Figlerowicz M, et al. Virus Res. 2012 May 18. [Epub ahead of print]

Structured Information Exchange on Infectious Diseases for Prisoners.

Flühmann P, Wassmer M, Schwendimann R. J Correct Health Care. 2012 May 17. [Epub ahead of print]

Impact of Donor Hepatitis C Virus Infection Status on Death and Need for Liver

Transplant in Hepatitis C Virus-Positive Kidney Transplant Recipients. Kucirka LM, Peters TG, Segev DL. Am J Kidney Dis. 2012 May 4. [Epub ahead of print]

Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. Jewett A, Smith BD, Garfein RS, et al. J Clin Virol. 2012 May 3. [Epub ahead of print]

Liver Cancer

Guideline on the use of new anticancer drugs for the treatment of Hepatocellular

Carcinoma 2010 update. Kaneko S, Furuse J, Kudo M, et al.Hepatol Res. 2012 Jun;42(6):523-542. doi: 10.1111/j.1872-034X.2012.00981.x.

Does transient elastography (FibroScan(®) ) have a role in decision making in hepatocellular carcinoma? Pesce A, Scilletta R, Branca A, et al. HPB (Oxford). 2012 Jun;14(6):403-8. doi: 10.1111/j.1477-2574.2012.00465.x. Epub

2012 Mar 28.

Is Serum Alpha-Fetoprotein Useful for Predicting Recurrence and Mortality Specific to Hepatocellular Carcinoma After Hepatectomy? A Test Based on Propensity Scores and Competing Risks Analysis. Shim JH, Yoon DL, Han S, et al. Ann Surg Oncol. 2012 May 30. [Epub ahead of print]

Role of Operative Therapy in Non-cirrhotic Patients with Metastatic

Hepatocellular Carcinoma. Zaydfudim V, Smoot RL, Clark CJ, et al. J Gastrointest Surg. 2012 May 30. [Epub ahead of print]

Hepatic arterial embolization for unresectable hepatocellular carcinomas: do

technical factors affect prognosis? Yamakado K, Miyayama S, Hirota S, et al.

Jpn J Radiol. 2012 May 30. [Epub ahead of print]

Hepatic artery injection of (131)I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study. Wu L, Yang YF, Ge NJ, et al. Eur J Nucl Med Mol Imaging. 2012 May 16. [Epub ahead of print]

Growth arrest-specific homeobox is associated with poor survival in patients with hepatocellular carcinoma. Zhou P, Chen Z, Chang RM, et al. Med Oncol. 2012 May 27. [Epub ahead of print]

Bevacizumab and Erlotinib in Previously Untreated Inoperable and Metastatic

Hepatocellular Carcinoma. Govindarajan R, Siegel E, Makhoul I, Williamson S. Am J Clin Oncol. 2012 May 24. [Epub ahead of print]

Diabetes Mellitus Is Associated with Increased Mortality in Patients Receiving Curative Therapy for Hepatocellular Carcinoma. Shau WY, Shao YY, Yeh YC, et al. Oncologist. 2012 May 23. [Epub ahead of print]

Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in

vitro and in vivo. Wang L, Jia D, Duan F, et al. Biochem Biophys Res Commun. 2012 May 22. [Epub ahead of print]

Chemoembolization With Doxorubicin-Eluting Beads for Unresectable Hepatocellular

Carcinoma: Five-Year Survival Analysis. Malagari K, Pomoni M, Moschouris H, et al. Cardiovasc Intervent Radiol. 2012 May 22. [Epub ahead of print]

A Randomized Controlled Trial of Radiofrequency Ablation and Surgical Resection in the Treatment of Small Hepatocellular Carcinoma. Feng K, Yan J, Li X, J et al. Hepatol. 2012 May 22. [Epub ahead of print]

Liver Transplantation for Hepatocellular Carcinoma: Long-Term Results Suggest Excellent Outcomes. Doyle MB, Vachharajani N, Maynard E, et al. J Am Coll Surg. 2012 May 17. [Epub ahead of print]

Efficacy of Laparoscopic Surgery for Recurrent Hepatocellular Carcinoma.

Et al.  J, Tamura A, Kaneko H. Hepatogastroenterology. 2012 May 16;59(117). doi: 10.5754/hge12302. [Epub ahead of print]